Process: Immuno-checkpoint inhibitor therapy accelerates the progression of atherosclerosis plaques

Immuno checkpoint inhibitors (ICIs) are widely used in cancer treatment.
consistent basic data show that these same checkpoints are key negative regulators for atherosclerosis.
study aims to see if ICI accelerates atherosclerosis and increases the risk of cardiovascular events associated with atherosclerosis.
study, which included 2,842 patients and 2,842 controls, initially analyzed the correlation between ICI exposure and atherosclerosis cardiovascular events and layered them according to age, cardiovascular history, and cancer type.
, the study also carried out cross-analysis of cases, 2 years before treatment for control, 2 years after treatment for the analysis group.
end of the disease is the combined outcome of atherosclerosis cardiovascular disease events (myocardial infarction, coronary bridge and ischemic stroke).
, the researchers compared the progress rate of atherosclerotic plaques before and after ICI treatment in the Imaging Subgroup Study (n-40).
the cumulative risk of cardiovascular events in patients treated with or without ICI in the matching queue study, cancer patients had a three-fold increased risk of cardiovascular events after receiving ICI treatment (risk ratio of 3.3,95% CI 2.0-5.5, p.lt;0.001).
similar risk increases in the component indicators of major outcomes.
cross-queue cardiovascular events in case cross-analysis, the risk of cardiovascular events increased after 2 years of ICI treatment, from 1.37/100 to 6.55/100 years (correction risk ratio 4.8,95% CI 3.5-6.5, p.lt;0.001).
in the imaging subgroup study, the progress rate of total aortic plaque volume in ICI treatment increased threefold (2.1%/year to 6.7%/year).
correlation between increased use of ICI and atherosclerotic plaques decreased with the use of statins or corticosteroid hormones.
, the high incidence of cardiovascular events in cancer patients treated with ICI may be due to the accelerated progression of atherosclerosis.
patients who use or intend to be treated with ICI should consider cardiovascular risk factors to raise awareness of cardiovascular event risk during treatment.
。